|
Post by dayanand33 on May 22, 2015 17:37:42 GMT
STEM broke out today on a BUY rating by Cantor-Fitzgerald last night. I had bought some shares on 20th of may. Sold them today for 10% gain. I think it will give away part of the gains made today. Hoping to buy back again on any dips.
|
|
|
Post by JHam on May 26, 2015 13:44:38 GMT
STEM continues to push forward. Nice job for those of you who were looking at $.70 as a target.
|
|
|
Post by dayanand33 on Jun 1, 2015 16:46:00 GMT
STEM continues to push forward. Nice job for those of you who were looking at $.70 as a target. Added some more at $0.66 based on past trends, I am anticipating a pumpy SA article in the next week or so.
|
|
|
Post by dayanand33 on Jun 2, 2015 17:07:20 GMT
|
|
|
Post by jckrdu on Jun 3, 2015 23:11:23 GMT
Will probably run higher before 6/24, but I sold some today to buy another stock that took a dive today.
|
|
|
Post by RLC on Jun 4, 2015 13:03:06 GMT
finance.yahoo.com/news/stemcells-inc-announces-commencement-second-120500803.htmlStemCells, Inc. Announces Commencement of the Second Cohort of the Pathway Study in Cervical Spinal Cord Injury
NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that it has enrolled its first subject in Cohort 2 of its Phase II Pathway Study. The study is designed to assess the efficacy of the Company's proprietary HuCNS-SC(R) platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury. Cohort 2 will enroll 40 patients and forms the single-blinded controlled arm of the Phase II study. The primary efficacy outcome being tested in Cohort 2 is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord. The Pathway Study is the first clinical trial designed to evaluate both the safety and efficacy of human neural stem cells transplanted into the spinal cord of patients with cervical spinal cord injury. Traumatic injuries to the neck can damage the cervical spinal cord and result in impaired sensation and motor function of the arms, legs, and trunk, also referred to as quadriplegia. The trial has 3 cohorts. The primary Cohort is Cohort 2 which is being conducted as a randomized, controlled, single-blind Cohort and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The trial will follow the participants for one year and will enroll up to 52 subjects. Cohort 1 of the Pathway Study is an open-label, HuCNS-SC dose-escalation arm involving six patients. Safety data from all six subjects was reviewed by an independent Data Monitoring Committee and approval was provided to commence with Cohort 2. No safety or tolerability issues were seen at any of the dosing levels. The six-month outcome from Cohort 1 will be disclosed as interim data later this year. Cohort 3 is an optional open label Cohort targeted to enroll 6 patients. This Cohort is designed to assess safety and preliminary efficacy in patients with less severe injuries (AIS C). "The initiation of Cohort 2 begins the next phase of our clinical efforts towards a potential breakthrough therapy for spinal cord injury," said Stephen Huhn, M.D., FACS, FAAP, Vice President, Clinical Research and Chief Medical Officer at StemCells, Inc. "This is the first blinded, controlled clinical trial to be conducted using human neural stem cells. The goal of this proof-of-concept study is to demonstrate the potential efficacy of our cells as a treatment for victims of spinal cord injury. We currently have seven sites enrolling patients and expect to reach a total of fourteen active North American sites by year end. Conducting a multi-center study on this scale should allow us to efficiently enroll the study." The Company completed enrollment and dosing in its open-label Phase I/II study in thoracic spinal cord injury in April 2014 and has reported top-line results. Sustained post-transplant gains in sensory function were demonstrated in seven of the twelve patients. Two patients in the Phase I/II study converted from a complete injury (AIS A) to an incomplete injury (AIS B). The final results also continue to confirm the favorable safety profile of the cells and the surgical procedure.
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Jun 26, 2015 14:09:09 GMT
|
|
|
Post by JHam on Jun 26, 2015 14:27:16 GMT
|
|
|
Post by lovie350z on Jun 26, 2015 15:15:23 GMT
Got out on Tuesday. Very small profit, didn't have it in me to hold.
|
|
|
Post by jckrdu on Jun 26, 2015 15:31:23 GMT
Sold the rest of my remaining small position... half yesterday before results and the other half this morning.
|
|
|
Post by dayanand33 on Jun 29, 2015 15:50:15 GMT
had sold 2/3 of my position at .71 on Thursday morning. Bought back some of it at .505 today. I think today's sell of is mainly due to Greek debt worries and pps of the small caps will recover in a couple of days.
|
|
|
Post by JHam on Jun 29, 2015 15:56:05 GMT
had sold 2/3 of my position at .71 on Thursday morning. Bought back some of it at .505 today. I think today's sell of is mainly due to Greek debt worries and pps of the small caps will recover in a couple of days. I think the overall market is down due to Greece. However some are down worse than others. What do you think of STEM's data? Personally, I thought it sucked and am wondering if this spells the same for the spinal trial.
|
|
|
Post by jckrdu on Jun 29, 2015 16:12:04 GMT
had sold 2/3 of my position at .71 on Thursday morning. Bought back some of it at .505 today. I think today's sell of is mainly due to Greek debt worries and pps of the small caps will recover in a couple of days. I think the overall market is down due to Greece. However some are down worse than others. What do you think of STEM's data? Personally, I thought it sucked and am wondering if this spells the same for the spinal trial. Dry AMD data was not good, as the independent group that did additional analysis did not report positive findings. Too much uncertainty.
I do intend to take a position in STEM prior to spinal data release in late 2015, but the problem at this point is that IMO STEM will need to do a reverse split to maintain their NASDAQ listing. If you go to their past PRs from 1-2 months ago, they lay out their options. I'm going to wait to see if they do the reverse before spinal results are announced later this year, and will buy-in on that fear.
|
|
|
Post by dayanand33 on Jun 29, 2015 16:15:29 GMT
had sold 2/3 of my position at .71 on Thursday morning. Bought back some of it at .505 today. I think today's sell of is mainly due to Greek debt worries and pps of the small caps will recover in a couple of days. I think the overall market is down due to Greece. However some are down worse than others. What do you think of STEM's data? Personally, I thought it sucked and am wondering if this spells the same for the spinal trial. The post-hoc assessment done by the reading center did put a dent into my confidence. The market did punish the stock on Friday. Today's fall is mostly related to Greece problems. In regards to the spinal trial, I am hopeful that we will see some positive data because other companies using Neural stem cells like CUR and Reneuron show promise in the treatment of central nervous system (spine and brain) related diseases. I am certainly not anticipating a home run but hoping to see a small rise in the pps. My position is short term and plan to sell in a couple of days.
|
|
|
Post by JHam on Jun 29, 2015 16:23:24 GMT
I think the overall market is down due to Greece. However some are down worse than others. What do you think of STEM's data? Personally, I thought it sucked and am wondering if this spells the same for the spinal trial. The post-hoc assessment done by the reading center did put a dent into my confidence. The market did punish the stock on Friday. Today's fall is mostly related to Greece problems. In regards to the spinal trial, I am hopeful that we will see some positive data because other companies using Neural stem cells like CUR and Reneuron show promise in the treatment of central nervous system (spine and brain) related diseases. I am certainly not anticipating a home run but hoping to see a small rise in the pps. My position is short term and plan to sell in a couple of days. Good rundown dayanand. The overall market is down today due to Greece but STEM got crushed on Friday due to the AMD data and imagine it would have been red today regardless of Greece. I agree with with Jckrdu that they are headed for another r/s. How couldn't they not at this point? Unfortunately this is one of the not-so-good situations in which to r/s (to avoid being delisted). So I will continue to stay away for the time being. Good luck!
|
|
|
Post by dayanand33 on Jun 30, 2015 19:57:39 GMT
I think the overall market is down due to Greece. However some are down worse than others. What do you think of STEM's data? Personally, I thought it sucked and am wondering if this spells the same for the spinal trial. The post-hoc assessment done by the reading center did put a dent into my confidence. The market did punish the stock on Friday. Today's fall is mostly related to Greece problems. In regards to the spinal trial, I am hopeful that we will see some positive data because other companies using Neural stem cells like CUR and Reneuron show promise in the treatment of central nervous system (spine and brain) related diseases. I am certainly not anticipating a home run but hoping to see a small rise in the pps. My position is short term and plan to sell in a couple of days. sold today at $.54 I was betting on some recovery today and it did. Made about 8% on a day's trade. I also sold an older lot that I bought at $1.0 for about 50% loss. I am now completely out of STEM but will keep watching it. There is a lot of negative sentiment around this stock that could result in a downward drift. May buy in if it dips 20-30% from the current levels.
|
|
|
Post by dayanand33 on Nov 12, 2015 16:07:23 GMT
|
|
|
Post by dayanand33 on Nov 17, 2015 18:33:54 GMT
Down 6% before tomorrow's webcast. This could be because of traders booking profit or news leak. I fear the latter and hence closed my position.
|
|
|
Post by johank on Nov 18, 2015 21:48:04 GMT
|
|
|
Post by dayanand33 on Jan 13, 2016 15:07:44 GMT
|
|